About RxSight
RxSight is a publicly listed company based in Aliso Viejo (United States) founded in 1997. Adjustable intraocular lens technology is developed using UV-sensitive macromers. RxSight has raised $198.73 million across 12 funding rounds from investors including RA Capital, Oxford Finance and Flying L Partners. The company has 498 employees. Its website rxsight.com draws about 13 thousand monthly visits. RxSight offers products and services including Light Adjustable Lens, Light Adjustable Lens+, and Light Delivery Device. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include Atia Vision, STAAR Surgical and WaveTec Vision; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 1997 and headquartered in Aliso Viejo, United States, RxSight operates in the medical device sector focused on ophthalmology. An adjustable intraocular lens platform has been engineered, incorporating biocompatible materials responsive to targeted ultraviolet wavelengths. Photopolymerization is induced upon exposure, enabling precise alterations to lens curvature for customized vision outcomes. Operations center on advancing this technology for cataract surgery applications, with ongoing development conducted from the U.S. base.
- Annual Revenue$134.48 M (USD)-3.89as on Dec 31, 2025
- Net Profit-$38.94 M (USD)-41.85as on Dec 31, 2025
- EBITDA-$44.92 M (USD)-35.18as on Dec 31, 2025
- Total Equity Funding$198.73M (USD)
in 12 rounds
- Latest Funding Round$60M (USD), Debt – Conventional
Dec 2020
- InvestorsRA Capital
& 5 more
- Employee Count498
Products & Services of RxSight
RxSight offers a comprehensive portfolio of products and services, including Light Adjustable Lens, Light Adjustable Lens+, and Light Delivery Device.
Customizable lens for post-cataract vision adjustment and astigmatism correction.
Enhanced version for vision correction after eye surgery.
Device for adjusting lenses post-surgery to improve visual acuity.
Apps and channels of RxSight
its YouTube channel RxSight has 870 subscribers and 30 videos.
Videos from RxSight
The most watched videos on RxSight's YouTube channel, RxSight (870 subscribers). Click a video to play it here.
More on RxSight.
Funding Insights of RxSight
RxSight has successfully raised a total of $198.73M across 12 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $60 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $198.73M
- Total Rounds 12
- Last Round Debt – Conventional — $60M
- First Round $30,209
(Jul 2002)
- Investors Count 6
Latest 10 of 12 funding rounds of RxSight with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $60M | Debt – Conventional | – | – | |
| Apr 2017 | $49.98M | Series H | – | – | – |
| Mar 2017 | $25M | Series H | – | – | |
| Jun 2015 | $69M | Series D | – | Longitude Capital | |
| Mar 2014 | $12.72M | Series C | – | – | – |
| Oct 2011 | $5.13M | Series B | – | – | – |
| Oct 2011 | $5.13M | Series B | – | – | – |
| Aug 2010 | $8.54M | Series B | – | – | – |
| Jun 2007 | $15M | Series B | – | – | – |
| Jun 2005 | $1.8M | Series A | – | – | – |
6 investors in total: 6 institutional.
Investors in RxSight
RxSight has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Oxford Finance and Flying L Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Flying L Partners is focused on ophthalmic sector investments. | flyinglpartners.com | |||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Balance Point Capital is engaged in providing flexible capital solutions. | 2007 | balancepointcapital.com | Westport, United States | |
| higbio.com | ||||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for RxSight
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RxSight
121 people are tracked at RxSight (45 in leadership, 8 in board & advisors, 68 in team); the tracked headcount is 498.
| Name | Role | Group |
|---|---|---|
Debe Deck | VP, Regulatory Affairs | Leadership |
Victoria Piunova | VP, LAL Chemistry | Leadership |
Steve Everly | VP, US Sales | Leadership |
Chris Sandstedt | VP, IOL Development | Leadership |
Lora C. | Director Of Reporting & Technical Accounting | Leadership |
Kim Arakaki | Associate Director, Commercial Operations | Leadership |
Ilya Goldshleger | COO | Leadership |
Ron Kurtz | MD, President & CEO | Leadership |
Shelley Thunen | CFO | Leadership |
Neil W Ackerson | Director Of Sales | Leadership |
Llainna Brecht | Associate Director, Accounting | Leadership |
Dexter G. | Associate Director, Global Planning | Leadership |
Jonathan Brydon | Director Of Sales, South Central Region | Leadership |
Josh L. | Senior Director, Corporate Fp&a | Leadership |
Jayne Oh | Senior Director Of Accounting | Leadership |
David Goffredo | Director, Clinical Projects | Leadership |
Brian McDevitt | Regional Business Director, West | Leadership |
Stephanie Stamoolis | Director Medical Affairs | Leadership |
Allison Knox | Customer Development Director, East | Leadership |
Diana Brown | Director Clinical Field Operations | Leadership |
101 more people are available in the full profile.
Complete people profiles for RxSight
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of RxSight
RxSight is a publicly listed company on the NASDAQ with ticker symbol RXST in USA, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jul 2021
- Listed onNASDAQ: RXST
- Listed entityRxSight, Inc.
- Exchange sectorElectronic technology
- ISINUS78349D1072
- Share price$4.53 (-2.79% on the day) · 2026-10-13
- Market capitalisation$188.4M
- EPS (diluted, trailing year)$-1.14
- Volume (last session)694,860
Financials of RxSight
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $134.5M | -$38.9M | -$44.9M |
| 2024 | $139.9M | -$27.4M | -$33.2M |
| 2023 | $89.1M | -$48.6M | -$45.8M |
| 2022 | $49.0M | -$66.8M | -$59.3M |
| 2021 | $22.6M | -$48.7M | -$48.8M |
Detailed financial statements for RxSight
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of RxSight
4 dated milestones of RxSight across 24 years, from founding to its latest funding, stage changes and deals.
- Founded RxSight is founded.
- Funding First funding round of $30K.
- Funding Latest funding round, Debt – Conventional, of $60.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of RxSight
RxSight has 3 listed competitors in our database, 2 of them funded. They include Atia Vision, STAAR Surgical and WaveTec Vision.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atiavision.com | 2012 | Campbell, United States | $67M | A presbyopia-correcting intraocular lens is developed for cataract patients. | ||
| staar.com | 1982 | Monrovia, United States | 1,115 | Manufacturer of implantable lenses for the eye with companion delivery systems | ||
| wavetecvision.com | 1997 | Aliso Viejo, United States | $85.16M | 64 | Intraoperative guidance for IOL alignment in cataract surgery is offered. |
Detailed competitors of RxSight
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of RxSight
The website of RxSight (rxsight.com) receives about 12.6K visits a month.
- Monthly visits12.6K
▼ 9% vs previous month
Websites whose visitors overlap most with RxSight. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clevelandeyeclinic.com | 100% | #1,224,290 | View details | ||
myayan.com | myayan.com | 89% | – | ||
changcataract.com | changcataract.com | 83% | #3,177,635 | – | |
vision-institute.com | vision-institute.com | 83% | #1,906,639 | – |
Top companies in Ophthalmology
3 companies that operate in the same segment as RxSight (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rxsight
Complete news archive for RxSight
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RxSight
RxSight was founded in 1997 and raised its 1st funding round 5 years after it was founded.
RxSight is headquartered in Aliso Viejo, United States. It is registered at Aliso Viejo, California, United States.
RxSight is a funded company, having raised a total of $198.73M across 12 funding rounds to date. The company's 1st funding round was a Series A of $1.8M, raised on Jul 2002.
RxSight has 498 employees.
Annual revenue of RxSight is $134.48M as on Dec 31, 2025.
Founded in 1997 and headquartered in Aliso Viejo, United States, RxSight operates in the medical device sector focused on ophthalmology. An adjustable intraocular lens platform has been engineered, incorporating biocompatible materials responsive to targeted ultraviolet wavelengths. Photopolymerization is induced upon exposure, enabling precise alterations to lens curvature for customized vision outcomes. Operations center on advancing this technology for cataract surgery applications, with ongoing development conducted from the U.S. base.
RxSight's top competitors include Atia Vision, STAAR Surgical and WaveTec Vision.
RxSight offers Light Adjustable Lens, Light Adjustable Lens+, and Light Delivery Device.
Yes, RxSight is publicly traded on NASDAQ under the ticker symbol RXST.
RxSight has 6 investors. Key investors include RA Capital, Oxford Finance, Flying L Partners, HIG BioHealth Partners, and Longitude Capital.